427 related articles for article (PubMed ID: 31958290)
1. Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy.
Garon EB; Scagliotti GV; Gautschi O; Reck M; Thomas M; Iglesias Docampo L; Kalofonos H; Kim JH; Gans S; Brustugun OT; Orlov SV; Cuyun Carter G; Zimmermann AH; Oton AB; Alexandris E; Lee P; Wolff K; Stefaniak VJ; Socinski MA; Pérol M
ESMO Open; 2020 Jan; 5(1):. PubMed ID: 31958290
[TBL] [Abstract][Full Text] [Related]
2. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.
Garon EB; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Gorbunova V; Kowalyszyn RD; Pikiel J; Czyzewicz G; Orlov SV; Lewanski CR; Thomas M; Bidoli P; Dakhil S; Gans S; Kim JH; Grigorescu A; Karaseva N; Reck M; Cappuzzo F; Alexandris E; Sashegyi A; Yurasov S; Pérol M
Lancet; 2014 Aug; 384(9944):665-73. PubMed ID: 24933332
[TBL] [Abstract][Full Text] [Related]
3. Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer.
Pérol M; Winfree KB; Cuyun Carter G; Lin Cui Z; Bowman L; Garon EB
Lung Cancer; 2019 May; 131():6-13. PubMed ID: 31027699
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcomes by histology in REVEL: A randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer.
Paz-Ares LG; Pérol M; Ciuleanu TE; Kowalyszyn RD; Reck M; Lewanski CR; Syrigos K; Arrieta O; Prabhash K; Park K; Pikiel J; Göksel T; Lee P; Zimmermann A; Carter GC; Alexandris E; Garon EB
Lung Cancer; 2017 Oct; 112():126-133. PubMed ID: 29191585
[TBL] [Abstract][Full Text] [Related]
5. Quality of life results from the phase 3 REVEL randomized clinical trial of ramucirumab-plus-docetaxel versus placebo-plus-docetaxel in advanced/metastatic non-small cell lung cancer patients with progression after platinum-based chemotherapy.
Pérol M; Ciuleanu TE; Arrieta O; Prabhash K; Syrigos KN; Goksel T; Park K; Kowalyszyn RD; Pikiel J; Lewanski CR; Thomas M; Dakhil S; Kim JH; Karaseva N; Yurasov S; Zimmermann A; Lee P; Carter GC; Reck M; Cappuzzo F; Garon EB
Lung Cancer; 2016 Mar; 93():95-103. PubMed ID: 26898621
[TBL] [Abstract][Full Text] [Related]
6. Outcomes in patients with aggressive or refractory disease from REVEL: A randomized phase III study of docetaxel with ramucirumab or placebo for second-line treatment of stage IV non-small-cell lung cancer.
Reck M; Paz-Ares L; Bidoli P; Cappuzzo F; Dakhil S; Moro-Sibilot D; Borghaei H; Johnson M; Jotte R; Pennell NA; Shepherd FA; Tsao A; Thomas M; Carter GC; Chan-Diehl F; Alexandris E; Lee P; Zimmermann A; Sashegyi A; Pérol M
Lung Cancer; 2017 Oct; 112():181-187. PubMed ID: 29191593
[TBL] [Abstract][Full Text] [Related]
7. Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study.
Garon EB; Winfree KB; Molife C; Cui ZL; Arriola E; Levy B; Mekhail T; Pérol M
Support Care Cancer; 2021 Jan; 29(1):117-125. PubMed ID: 32318871
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy.
Yoh K; Hosomi Y; Kasahara K; Yamada K; Takahashi T; Yamamoto N; Nishio M; Ohe Y; Koue T; Nakamura T; Enatsu S; Lee P; Ferry D; Tamura T; Nakagawa K
Lung Cancer; 2016 Sep; 99():186-93. PubMed ID: 27565938
[TBL] [Abstract][Full Text] [Related]
9. A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale and study design.
Garon EB; Cao D; Alexandris E; John WJ; Yurasov S; Perol M
Clin Lung Cancer; 2012 Nov; 13(6):505-9. PubMed ID: 22853980
[TBL] [Abstract][Full Text] [Related]
10. The efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer.
Sakaguchi T; Furuya N; Ito K; Hida N; Morikawa K; Komase Y; Inoue T; Hataji O; Mineshita M
Thorac Cancer; 2020 Jun; 11(6):1559-1565. PubMed ID: 32291896
[TBL] [Abstract][Full Text] [Related]
11. Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer.
Katayama Y; Yamada T; Sawada R; Kawachi H; Morimoto K; Watanabe S; Watanabe K; Takeda T; Chihara Y; Shiotsu S; Hibino M; Harada T; Nishioka N; Iwasaku M; Tokuda S; Takayama K
Oncologist; 2024 May; 29(5):e681-e689. PubMed ID: 38241181
[TBL] [Abstract][Full Text] [Related]
12. East Asian Subgroup Analysis of a Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL).
Park K; Kim JH; Cho EK; Kang JH; Shih JY; Zimmermann AH; Lee P; Alexandris E; Puri T; Orlando M
Cancer Res Treat; 2016 Oct; 48(4):1177-1186. PubMed ID: 26910471
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.
Ramalingam SS; Pérol M; Reck M; Kowalyszyn RD; Gautschi O; Kimmich M; Cho EK; Czyzewicz G; Grigorescu A; Karaseva N; Dakhil S; Lee P; Zimmerman A; Sashegyi A; Alexandris E; Carter GC; Winfree KB; Garon EB
Clin Lung Cancer; 2018 May; 19(3):270-279.e3. PubMed ID: 29373274
[TBL] [Abstract][Full Text] [Related]
14. Exposure-response relationship for ramucirumab from the randomized, double-blind, phase 3 REVEL trial (docetaxel versus docetaxel plus ramucirumab) in second-line treatment of metastatic non-small cell lung cancer.
Smit EF; Garon EB; Reck M; Cappuzzo F; Bidoli P; Cohen RB; Gao L; O'Brien LM; Lee P; Zimmermann A; Ferry DR; Melemed AS; Pérol M
Cancer Chemother Pharmacol; 2018 Jul; 82(1):77-86. PubMed ID: 29721850
[TBL] [Abstract][Full Text] [Related]
15. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.
Kim ES; Neubauer M; Cohn A; Schwartzberg L; Garbo L; Caton J; Robert F; Reynolds C; Katz T; Chittoor S; Simms L; Saxman S
Lancet Oncol; 2013 Dec; 14(13):1326-36. PubMed ID: 24231627
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
[TBL] [Abstract][Full Text] [Related]
18. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Docetaxel plus Ramucirumab for Patients with Pretreated Advanced or Recurrent Non-small Cell Lung Cancer: Focus on Older Patients.
Onoi K; Yamada T; Morimoto K; Kawachi H; Tsutsumi R; Takeda T; Okada A; Tamiya N; Chihara Y; Shiotsu S; Takemura Y; Yamada T; Hasegawa I; Katayama Y; Iwasaku M; Tokuda S; Takayama K
Target Oncol; 2024 May; 19(3):411-421. PubMed ID: 38467958
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
